Predicting how a person’s heart will respond to a new medicine remains one of the most persistent blind spots in drug development. Even with decades of scientific progress, cardiotoxicity can still emerge unexpectedly, carrying enormous financial costs and, more importantly, real human consequences. Today, that challenge is being met with a bold new vision.

InSilicoTrials is proud to lead with The Jackson Laboratory (JAX) under the leadership of Dr. Matt Mahoney, principal computational scientist, alongside The New York Stem Cell Foundation, UConn Health, and the University of Michigan, in CARDIOVERSE, a groundbreaking initiative funded by up to $30 million from the Advanced Research Projects Agency for Health (ARPA-H) through its bold CATALYST program, led by Dr. Andy Kilianski. Together, this consortium will create the next generation of virtual heart models capable of representing the genetic, physiological, and demographic diversity of the American population, fundamentally transforming cardiac safety prediction.

“It is great to have InSilicoTrials as a partner in the CARDIOVERSE team. Their validated computational models, including cardiotoxicity tools already trusted across the industry, add valuable scientific and technical strength to this initiative. Their ability to translate complex biology into practical, regulatory-aligned digital evidence brings essential rigor. With their experience alongside the expertise of our broader team, we can take important steps toward cardiac safety assessments that better reflect human physiology and improve how new medicines are developed.” commented Mary Dickinson, Executive Vice President and Chief Scientific Officer at The Jackson Laboratory.

CARDIOVERSE is more than a scientific project; it is a multidisciplinary effort uniting stem cell innovation, experimental cardiology, computational biology, and AI. InSilicoTrials brings to this collaboration its cloud-based / technology platform, built on years of work developing regulatory-grade simulation tools, supporting studies aligned with the FDA and EMA, and delivering cloud-based modeling to pharmaceutical and biotech companies globally. Beyond these capabilities, InSilicoTrials has already developed established cardiotoxicity models used by the life sciences industry to assess proarrhythmic risk and drug–heart interactions, expertise that directly strengthens its role in CARDIOVERSE and elevates the scientific impact of the consortium.

This project builds naturally on InSilicoTrials’ mission: to make in silico evidence accessible, reliable, and impactful at every stage of development. CARDIOVERSE allows the company to expand that mission into cardiotoxicity with unprecedented depth, integrating living-cell data, high-fidelity simulations, and virtual populations to help researchers see risks that were previously invisible.

CARDIOVERSE is one of the flagship initiatives within the CATALYST program, ARPA-H’s visionary effort to shift early-stage drug safety away from traditional animal models toward human-relevant digital systems. By contributing advanced mathematical modeling, AI-driven prediction, and proven experience in regulatory pathways, the project will help transform how cardiac safety is evaluated, before a drug ever reaches a human heart.

About InSilicoTrials

InSilicoTrials is a digital health startup founded by experts in life sciences, cybersecurity, and digital innovation. Its cloud-based platform leverages AI and simulation to predict drug safety and efficacy, accelerate R&D, and streamline clinical trial processes for pharmaceutical, biotech, and research organizations. With a global network of more than 70 scientific partners and hundreds of integrated models, InSilicoTrials is helping organizations modernize and improve drug development workflows.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251222203788/en/